Disclosed are compositions and methods for treating inflammation including its end-stage sepsis and conditions mediated by inflammation such as liver apoptosis and cirrhosis, thrombocytopenia, hypoglycogenemia, hyperglycemia, and hypertriglyceridemia. In one aspect, the compositions and methods disclosed herein can also be used to enhance clearance of microbes from infected tissues, organs, or systems in a subject. Also disclosed herein are compositions and methods for reducing levels of stress responsible transcription factors and metabolic transcription factors in a cell in a subject with microbial, allergic, autoimmune, metabolic, and posttraumatic inflammation.

Disclosed are compositions and methods for treating inflammation including its end-stage sepsis and conditions mediated by inflammation such as liver apoptosis and cirrhosis, thrombocytopenia, hypoglycogenemia, hyperglycemia, and hypertriglyceridemia. In one aspect, the compositions and methods disclosed herein can also be used to enhance clearance of microbes from infected tissues, organs, or systems in a subject. Also disclosed herein are compositions and methods for reducing levels of stress responsible transcription factors and metabolic transcription factors in a cell in a subject with microbial, allergic, autoimmune, metabolic, and posttraumatic inflammation.

The instant disclosure provides methods and compositions related to discovery of a long-acting FGF21 as a therapeutic target for treatment or prevention of neovascular eye diseases or disorders that are characterized by angiogenesis, or of vascular diseases of the eye. Therapeutic and/or prophylactic uses and compositions of long-acting FGF21 are described.

Therapeutic regimens and uses of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates comprising a polyethylene glycol (PEG) moiety attached to a mutant FGF-21 peptide via a glycosyl moiety thereof in the reduction of total body weight, reduction of body fat content, and/or reduction of BMI of the subject in need thereof are provided.

The present disclosure relates to the field of biotechnology, and in particular. to a fusion protein for the treatment of metabolic diseases, a preparation method therefor and use thereof. The present disclosure provides a fusion protein, including a Glucagon analogue fragment and a long-acting protein unit fragment, the Glucagon analogue fragment including: a) a polypeptide fragment having an amino acid sequence shown in SEQ ID No. 81; or b) a polypeptide fragment that has an amino acid sequence having at least 90% sequence identity with SEQ ID NO. 81 and has a function of the polypeptide fragment defined in a). The fusion protein of the present disclosure has good stability and good hypoglycemic and weight loss effects for mice.

The present disclosure relates to the field of biotechnology, and in particular. to a fusion protein for the treatment of metabolic diseases, a preparation method therefor and use thereof. The present disclosure provides a fusion protein, including a Glucagon analogue fragment and a long-acting protein unit fragment, the Glucagon analogue fragment including: a) a polypeptide fragment having an amino acid sequence shown in SEQ ID No. 81; or b) a polypeptide fragment that has an amino acid sequence having at least 90% sequence identity with SEQ ID NO. 81 and has a function of the polypeptide fragment defined in a). The fusion protein of the present disclosure has good stability and good hypoglycemic and weight loss effects for mice.

A recombinant vector according to an embodiment of the present invention may produce fibroblast growth factor 19 (FGF19) having enhanced solubility. The synonymous codon substitution variant fibroblast growth factor 19 (scvhFGF19) and chaperone ΔssDsbC may be simultaneously and independently expressed in a host cell into which the recombinant vector is introduced, thereby it is possible to overexpress the fibroblast growth factor 19 in a soluble state.

A recombinant vector according to an embodiment of the present invention may produce fibroblast growth factor 19 (FGF19) having enhanced solubility. The synonymous codon substitution variant fibroblast growth factor 19 (scvhFGF19) and chaperone ΔssDsbC may be simultaneously and independently expressed in a host cell into which the recombinant vector is introduced, thereby it is possible to overexpress the fibroblast growth factor 19 in a soluble state.

A method of making a synthetic foldable having a tertiary structure emulating the tertiary structure of a reference foldable protein is described. The method includes determining a folding nucleus peptide sequence associated with folding the reference foldable protein. The synthetic foldable protein is synthesized by including the determined folding nucleus peptide sequence and at least one repeat thereof in the peptide sequence of the synthetic foldable protein.

Described herein are modified fibroblast growth factor (FGF) polypeptides, pharmaceutical compositions and medicaments that include such modified FGF polypeptides, and methods of using such modified FGF polypeptides to treat or prevent conditions that benefit from administration of FGFs.